Twist Bioscience Corp vs Vanguard International High Dividend Yield ETF — how do they compare? Twist Bioscience Corp trades at $159.78 (market cap $10.08B), while Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 2.3× Twist Bioscience Corp's market cap, and Vanguard International High Dividend Yield ETF is more actively traded (748,441 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| TWST | VYMI | |
|---|---|---|
Market Cap | $10.08B | $22.80B |
Volume | 4,229,037 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $205.00 | $107.13 |
52-Week Low | $25.45 | $82.92 |
Typical Hold Time | 27 Days | 50 Days |
Enterprise Value | $10.01B | — |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
VYMI trades at $100.06, down 0.17% with bearish technical signals from moving averages. The ETF shows strong institutional interest with recent stake increases from Envestnet and Corient Private Wealth. Recent news highlights VYMI's 29% one-year return and 3.61% dividend yield, outperforming peers with lower fees. The fund's heavy financial sector exposure (43.6%) benefits from rising global interest rates.
VYMI presents a compelling international dividend growth opportunity with attractive valuation and income characteristics. Key risks include concentration in financials and sensitivity to global economic conditions. The ETF's low 0.07% expense ratio and strong historical performance support its appeal for income-focused investors seeking international diversification.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →